GlassScriptPhysician profile
Anil V Tumkur
NPI 1346288727
$13,754.64
in general payments reported to CMS, 2019-2025
72 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,812 · 2020: $2,048 · 2021: $2,193 · 2022: $2,291 · 2023: $2,052 · 2024: $1,712 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,132 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,131.72 |
| Education | $278.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $961.55 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $920.90 | 2019-2025 | Erleada, Tecvayli, Rybrevant |
| Novartis Pharmaceuticals Corporation | $912.59 | 2019-2025 | |
| Amgen INC. | $853.57 | 2019-2023 | Lumakras, Xgeva, Nplate |
| Pfizer INC. | $625.13 | 2019-2025 | |
| Genzyme Corporation | $618.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $588.43 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Gilead Sciences, INC. | $532.83 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $532.33 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $511.09 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $444.56 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Celgene Corporation | $411.86 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Genentech USA, INC. | $411.52 | 2019-2023 | Tecentriq, Perjeta, Phesgo |
| Eisai INC. | $383.86 | 2019-2024 | |
| Incyte Corporation | $337.69 | 2019-2022 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Tumkur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.